Jones Financial Companies
SPRO icon

Jones Financial Companies’s Spero Therapeutics SPRO Stock Holding History

Jones Financial Companies’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$17.9K Buy
7,678
+1,201
+19% +$2.85K ﹤0.01% 3338
2025
Q4 		$15.1K Buy
+6,477
New +$15K ﹤0.01% 3050

Other funds holding SPRO

GP
GSK plc London $599M AUM
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Jones Financial Companies's SPRO Position: Q1 2026 in Review

Jones Financial Companies increased its Spero Therapeutics (SPRO) stake by 19% in Q1 2026, buying an estimated $2.85K and bringing the position to 7,678 shares worth $17.9K. The position accounts for ﹤0.01% of the portfolio, ranked #3338.

Jones Financial Companies first reported a position in SPRO in Q4 2025 and has held it in 2 quarters since. 50 funds tracked by Wall St. Rank hold SPRO as of Q1 2026.

  • Jones Financial Companies held 7,678 shares of Spero Therapeutics worth $17.9K as of Q1 2026.
  • Jones Financial Companies bought 1,201 Spero Therapeutics shares in Q1 2026, an estimated $2.85K.
  • Spero Therapeutics made up ﹤0.01% of Jones Financial Companies's portfolio in Q1 2026, its #3338 holding.
  • Jones Financial Companies first reported a position in Spero Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 50 funds tracked by Wall St. Rank held Spero Therapeutics as of Q1 2026.

Based on Jones Financial Companies's 13F filing for Q1 2026, filed 15 May 2026.